Previous 10 | Next 10 |
PARSIPPANY, N.J., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, will host an industry-sponsored symposium at the Advanced Technologies & Treatments for Diabetes (ATTD) international ...
On Tuesday, shares of diabetes management company Embecta (NASDAQ: EMBC.V) managed a more than 12% rise in price. That was due to the impact of its latest set of quarterly results, which trounced analyst estimates for profitability and comfortably topped revenue expectations. Before m...
Embecta Corp. (EMBC) Q1 2023 Earnings Conference Call February 14, 2023 08:00 ET Company Participants Pravesh Khandelwal - Vice President, Investor Relations Dev Kurdikar - Chief Executive Officer Jake Elguicze - Chief Financial Officer Conference Call Participan...
The following slide deck was published by Embecta Corp. in conjunction with their 2023 Q1 earnings call. For further details see: Embecta Corp. 2023 Q1 - Results - Earnings Call Presentation
Embecta press release ( NASDAQ: EMBC ): Q1 Non-GAAP EPS of $0.96 beats by $0.44 . Revenue of $275.7M (-4.7% Y/Y) beats by $12.8M . Adjusted gross profit and margin of $188.9 million and 68.5%. Adjusted operating income and margin of $101.6 million and 36.9%. ...
PARSIPPANY, N.J., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, today reported financial results for the three month period ended December 31, 2022. "We are p...
Summary Dividends may not increase every year and a cut or elimination is even possible but the odds are greatly reduced when you diversify among different companies and sectors and focus on dividend quality. The market may move up and down irrationally and seemingly on a whim while our...
PARSIPPANY, N.J., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, today announced that management will participate in the following upcoming investor conferences: 2023 BTIG Medical...
Summary DexCom is young, innovative, admired, and (consequently) highly valued. Embecta is old, lethargic, lacks coverage, and (consequently) lowly valued. Growth and value investors may find respective equities interesting. I use DXCM and EMBC as a lens to view developments in ...
Summary Yacktman's 13F equity portfolio value increased from $9.17B to $10.04B this quarter. Yacktman Asset Management increased Charles Schwab while decreasing PepsiCo, Sysco, and Weatherford International. Yacktman’s largest five stakes are at ~26% of the portfolio. ...
News, Short Squeeze, Breakout and More Instantly...
PARSIPPANY, N.J., July 18, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal third quarter 2024 financial results, provide an operational upd...
PARSIPPANY, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, presented two abstracts at the American Diabetes Association’s 84 th Scientific Sessions that point to ...
2024-06-21 06:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...